MacroGenics Corp (MGNX) Earnings growth forecast for next year

MacroGenics, Inc. - graphic logo of issuer MGNX

The development of targeted antibodies guarantees MacroGenics, Inc. (MGNX) steady demand and patent revenues. The EPS growth forecast model for the coming year visualizes expert expectations, where -11.10 shows the value of this parameter. Current revenue is based on royalties from Margenza, although the expansion of biosimilars and fierce competition for investor attention in the oncology sector remain significant challenges.

MacroGenics Corp (MGNX): Expected earnings per share trend next year from 07/04/2022 to 11/14/2026

Analytical breakdowns and data insights for company macrogenics.com (MGNX)

- share price and consensus valuation forecast:
Stock Price MacroGenics Corp|MGNX - Consensus Target
- market capitalization details:
Market Capitalization MacroGenics|MGNX - Total Enterprise Value
- book capitalization indicators:
Net Assets per Single Share MacroGenics|MGNX - Accounting Value of Company|Market Value to Book Value Ratio macrogenics.com|MGNX - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital MacroGenics, Inc.|MGNX - Long-Term Debt to Capital|Short-Term Debt to Capital MacroGenics|MGNX - Company Total Debt|Debt to Book Capitalization Ratio MacroGenics|MGNX - Company Long-Term Loans and Borrowings|Company Short-Term Debt MacroGenics|Quick Ratio macrogenics.com
- net income and valuation ratios data:
MGNX - Annual Net Income|Projected Future Earnings MacroGenics, Inc.|MGNX - Market Cap to Earnings|Future Price to Earnings MacroGenics, Inc.|MGNX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple MacroGenics|MGNX - Operating income before deduction of amortization|Net earnings per share (EPS TTM) MacroGenics|MGNX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months macrogenics.com|MGNX - Expected net earnings per share growth this year|Expected earnings per share growth for next year MacroGenics, Inc.
- sales and revenue indicators:
MGNX - Company Sales Revenue|Projected Sales Volume MacroGenics Corp|MGNX - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio MacroGenics
Comprehensive company analysis:MGNX, MacroGenics Corp
Finished products of macrogenics.com

The resilience of MacroGenics, Inc. (MGNX) is driven by the successful development of targeted antibodies for the treatment of breast cancer. This price action reflecting the estimated annual EPS growth for the next period captures market confidence in the commercialization of the company's innovations. The metric aggregates analyst consensus earnings forecasts, making it possible to identify a reversal in fundamental momentum prior to earnings releases and adjust the asset's fair value.

Competitor analysis for MacroGenics, Inc.

OLMA (Olema Pharma) - Earnings growth forecast for next year|Expected earnings per share growth for next year Puma Biotechnology Inc (PBYI)|Earnings growth forecast for next year GLSI|ZNTL - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Plus Therapeutics PSTV|Expected earnings per share trend next year PCSA|EGRX - Net earnings per share growth forecast for next year